279 related articles for article (PubMed ID: 20430590)
1. Vascular endothelial growth factor (VEGF) in the pathogenesis of psoriasis--a possible target for novel therapies?
Canavese M; Altruda F; Ruzicka T; Schauber J
J Dermatol Sci; 2010 Jun; 58(3):171-6. PubMed ID: 20430590
[TBL] [Abstract][Full Text] [Related]
2. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration.
Ciulla TA; Rosenfeld PJ
Curr Opin Ophthalmol; 2009 May; 20(3):166-74. PubMed ID: 19381089
[TBL] [Abstract][Full Text] [Related]
3. Topical application of anti-angiogenic peptides based on pigment epithelium-derived factor can improve psoriasis.
Abe R; Yamagishi S; Fujita Y; Hoshina D; Sasaki M; Nakamura K; Matsui T; Shimizu T; Bucala R; Shimizu H
J Dermatol Sci; 2010 Mar; 57(3):183-91. PubMed ID: 20060688
[TBL] [Abstract][Full Text] [Related]
4. Angiogenesis--a new target for future therapy.
Pandya NM; Dhalla NS; Santani DD
Vascul Pharmacol; 2006 May; 44(5):265-74. PubMed ID: 16545987
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
6. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.
Hicklin DJ; Ellis LM
J Clin Oncol; 2005 Feb; 23(5):1011-27. PubMed ID: 15585754
[TBL] [Abstract][Full Text] [Related]
7. Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor.
Shibuya M
FEBS J; 2009 Sep; 276(17):4636-43. PubMed ID: 19664071
[TBL] [Abstract][Full Text] [Related]
8. Anti-angiogenic therapy against gastrointestinal tract cancers.
Iwasaki J; Nihira S
Jpn J Clin Oncol; 2009 Sep; 39(9):543-51. PubMed ID: 19531544
[TBL] [Abstract][Full Text] [Related]
9. VEGF and angiogenesis in acute and chronic MOG((35-55)) peptide induced EAE.
Roscoe WA; Welsh ME; Carter DE; Karlik SJ
J Neuroimmunol; 2009 Apr; 209(1-2):6-15. PubMed ID: 19233483
[TBL] [Abstract][Full Text] [Related]
10. Chapter 6. Mouse models to investigate anti-cancer effects of VEGF inhibitors.
Crawford Y; Ferrara N
Methods Enzymol; 2008; 445():125-39. PubMed ID: 19022058
[TBL] [Abstract][Full Text] [Related]
11. VGA1155, a novel binding antagonist of VEGF, inhibits angiogenesis in vitro and in vivo.
Ueda Y; Yamagishi T; Ikeya H; Hirayama N; Itokawa T; Aozuka Y; Samata K; Nakaike S; Tanaka M; Ono M; Saiki I
Anticancer Res; 2004; 24(5A):3009-17. PubMed ID: 15517909
[TBL] [Abstract][Full Text] [Related]
12. Role of the vascular endothelial growth factor isoforms in retinal angiogenesis and DiGeorge syndrome.
Stalmans I
Verh K Acad Geneeskd Belg; 2005; 67(4):229-76. PubMed ID: 16334858
[TBL] [Abstract][Full Text] [Related]
13. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
Pradeep CR; Sunila ES; Kuttan G
Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
[TBL] [Abstract][Full Text] [Related]
14. VEGF function in vascular pathogenesis.
Ng YS; Krilleke D; Shima DT
Exp Cell Res; 2006 Mar; 312(5):527-37. PubMed ID: 16330026
[TBL] [Abstract][Full Text] [Related]
15. Recombinant murine interleukin 4 protein therapy for psoriasis in a transgenic VEGF mouse model.
Ren X; Li J; Zhou X; Luo X; Huang N; Wang Y; Chen X; Wei Y
Dermatology; 2009; 219(3):232-8. PubMed ID: 19729876
[TBL] [Abstract][Full Text] [Related]
16. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
Shojaei F; Ferrara N
Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
[TBL] [Abstract][Full Text] [Related]
17. Histological and transcriptional study of angiogenesis and lymphangiogenesis in uninvolved skin, acute pinpoint lesions and established psoriasis plaques: an approach of vascular development chronology in psoriasis.
Henno A; Blacher S; Lambert CA; Deroanne C; Noël A; Lapière C; de la Brassinne M; Nusgens BV; Colige A
J Dermatol Sci; 2010 Mar; 57(3):162-9. PubMed ID: 20071151
[TBL] [Abstract][Full Text] [Related]
18. Targeting VEGF/VEGFR in the treatment of psoriasis.
Li W; Man XY; Chen JQ; Zhou J; Cai SQ; Zheng M
Discov Med; 2014 Sep; 18(98):97-104. PubMed ID: 25227750
[TBL] [Abstract][Full Text] [Related]
19. Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis.
McCrudden KW; Hopkins B; Frischer J; Novikov A; Huang J; Kadenhe A; New T; Yokoi A; Yamashiro DJ; Kandel JJ; Middlesworth W
J Pediatr Surg; 2003 Mar; 38(3):308-14; discussion 308-14. PubMed ID: 12632340
[TBL] [Abstract][Full Text] [Related]
20. VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development.
Larcher F; Murillas R; Bolontrade M; Conti CJ; Jorcano JL
Oncogene; 1998 Jul; 17(3):303-11. PubMed ID: 9690512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
